FAQs
- FAQs
Frequently Asked Questions
Q: What is ReVessel’s core technology?
ReVessel is developing the world’s first digital twin of human blood—an AI-powered simulation that replicates each individual’s hematologic and hemodynamic behavior with real-time responsiveness and encrypted data architecture.
Q: What is a digital twin?
A digital twin is a data-driven, virtual model of a physical system—designed to simulate, predict, and optimize performance in real time. ReVessel’s digital twin replicates the unique dynamics of an individual’s blood system, using AI and encrypted data layers to model biological behavior with precision. This unlocks a new category of infrastructure for health systems—one that transforms how blood is monitored, managed, and scaled across personalized care.
Q: Are blood shortages a big problem?
Yes. Blood shortages are a persistent challenge in the U.S. and globally, driven by declining donor numbers, eligibility restrictions, and rising demand. The U.S. has faced critical shortfalls in recent years, exposing the fragility of donor-dependent systems. ReVessel addresses this structural vulnerability by introducing a predictive, data-driven approach to blood management—reducing reliance on scarce inventory and enabling smarter, more resilient supply strategies.
Q: Is your service worldwide?
ReVessel is initially focused on the U.S. market, where we are aligning with clinical, regulatory, and infrastructure priorities to validate our platform. Our architecture is built for global scalability, with international expansion planned through targeted partnerships and high-impact health systems.
Q: What makes ReVessel different from traditional clinical decision tools and technology?
Most tools provide static insights based on past data. ReVessel continuously models live biological and systemic information, enabling real-time simulations and forward-looking predictions. Our architecture combines AI, blockchain, and confidential computing for performance, privacy, and governance at scale.
Q: Is ReVessel commercially available?
ReVessel is currently in early-stage development and not yet commercially available. We are in ongoing discussions with clinical advisors, research institutions, and ecosystem partners to co-develop and validate the platform. As we advance our technology roadmap, we are actively seeking strategic investors and collaborators who share our vision for building the infrastructure behind personalized blood management.
Q: How does ReVessel integrate with existing hospital systems?
ReVessel is designed for interoperability. We support EMR, FHIR, OMOP, and other standard formats, enabling integration via secure APIs without requiring infrastructure overhaul. Edge deployment allows simulation and intelligence to be delivered directly at the point of care.